2:00 PM
Reliance Securities on Torrent Pharma
Torrent Pharmaceuticals (TRP) is a strong player in chronic segment in India and Unichem acquisition is a strategic fit for the Company as it would further strengthen its presence in key chronic therapy segment. TRP would be able to improve the profitability of Unichem’s product portfolio through its strong field force and distribution network.
Looking ahead, we expect a healthy growth in TRP’s domestic formulation (14.5% CAGR), Brazil (15.8% CAGR) and RoW (13.3% CAGR) business over FY17-19E.
We expect TRP’s Sales, EBITDA and PAT to witness 13%, 15% and 15% CAGR, respectively, while EBITDA margin is expected to improve by 100bps to 24.5% over FY17-19E.
We have not factored the impact of Unichem acquisition into our valuation model due to pending regulatory approvals. Envisaging a healthy growth in India and Brazil businesses led by new launches and improvement in sale force productivity, we maintain our BUY recommendation and Target Price of Rs 1,450, valuing the stock at 20x FY19E EPS of Rs 72.5.